This might be one reason:
Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress
Achillion Pharmaceuticals, Inc.
14 hours ago
- Two late breaker presentations detail previously announced 100% SVR12 in Phase 2 trial evaluating 6- or 8-weeks of treatment with ACH-3102 and sofosbuvir in genotype 1 HCV patients and Phase 1 proof-of-concept results with ACH-3422 -
- Clinical virology presentation continues to support improved barrier to resistance with ACH-3102 -
PITTSBURGH & WEST VIRGINIA RAILROAD and POWER REIT, Defendants.
AND NOW, this 22nd day of April, 2015, in accordance with the foregoing Memorandum
Opinion and Order of Court, it is hereby ORDERED, ADJUDGED and DECREED that
JUDGMENT is entered in favor of Plaintiffs Norfolk Southern Railway Company (“Norfolk
Southern”) and Wheeling & Lake Erie Railway Company (“Wheeling & Lake Erie”) and against Defendants Pittsburgh & West Virginia Railroad (“PWV”) and Power REIT
This doesn't sound like much of a commitment to buy back shares:
"The Company expects to begin considering share repurchases under the Program in the second quarter."
The buyout company and MCP bonds will own this company.
Also, I don't think the lenders would be too thrilled about a dividend declaration before they get the Q4 earnings.
Good point. That would put the cart before the horse or, in this case, the dividend before the earnings.
Right. The $190 million issue of 3.25% Convertible Notes is due in June 2016. The last 10Q commented on these notes in connection with terms of the Oaktree loan:
The interest rate paid to Oaktree will be higher "....unless our 3.25% Convertible Notes have been repaid in full with the proceeds of the sale of our common equity or by the exchange of such convertible notes for our common equity, or any combination thereof".
The Seeking Alpha article states that the author is short:.
"Feb. 19, 2015 9:20 AM ET | 24 comments | About: Molycorp, Inc. (MCP)
Disclosure: The author is short MCP. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article."
According to the last 10-Q, RCAP has 88.6 million shares outstanding. How is it that the current short interest of 11.8 million shares represents 71% of the "float"? I don't question your numbers because that is what is reported. But that would put the "float" at about 16.7 million shares. Who owns the "non-float" shares?
I hope you are right, but JONE has not traded above $15 since October 2014. $15 per share is a 50% increase from today's price.